Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 2000
Single User License Price INR 138000
Corporate User License Price USD 6000
Corporate User License Price INR 414000
Site License Price USD 4000
Site License Price INR 276000
Request a Quote

Report Title

Cough-Pipeline-Review-H2-2017

Quote Request for License Type
License Type Price  
Single User License USD 2000
Site License USD 4000
Enterprise Wide License USD 6000
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Cough-Pipeline-Review-H2-2017


Quote Request for License Type
License Type Price  
Single User License USD 2000
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Cough-Pipeline-Review-H2-2017

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Cough-Pipeline-Review-H2-2017



Executive Summary

Cough-Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cough-Pipeline Review, H2 2017, provides an overview of the Cough (Respiratory) pipeline landscape.

Cough is a common reflex action that aims to clear the throat of mucus or foreign irritants. Dry cough, chronic cough and whooping cough (also known as pertussis) are distinct types of cough. Symptoms include runny or stuffy nose, hoarseness, wheezing and shortness of breath, heartburn or a sour taste in mouth and rarely coughing up blood. The predisposing factors include asthma, chronic obstructive pulmonary disease, cigarette smoking, lung diseases such as bronchiectasis, interstitial lung disease, or tumors, lung infections such as pneumonia or acute bronchitis and allergic rhino sinusitis. Treatment includes cough suppressants, oral expectorants, and topical (externally applied) drugs.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cough-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Cough (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cough (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Cough and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 1, 7, 1, 10, 3 and 4 respectively.

Cough (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Cough (Respiratory).

The pipeline guide reviews pipeline therapeutics for Cough (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Cough (Respiratory) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Cough (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Cough (Respiratory)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Cough (Respiratory).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Cough (Respiratory) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Cough-Overview

Cough-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Cough-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Cough-Companies Involved in Therapeutics Development

Alitair Pharmaceuticals Inc

AstraZeneca Plc

BELLUS Health Inc

Charleston Laboratories Inc

Conrig Pharma ApS

Daewoong Pharmaceutical Co Ltd

Develco Pharma Schweiz AG

Grunenthal GmbH

Hyundai Pharmaceutical Co Ltd

Merck & Co Inc

Orbis Biosciences Inc

Patara Pharma Inc

PhytoHealth Corp

Pila Pharma AB

SolAeroMed Inc

Vernalis Plc

Cough-Drug Profiles

AX-8-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

benzonatate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BLU-5937-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CCP-05-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CCP-06-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CCP-07-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CCP-08-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CLX-121-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

codeine + guaifenesin-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cromolyn sodium-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DWJ-1340-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

gefapixant-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

guaifenesin + hydrocodone-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

guaifenesin ER-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

hydrocodone bitartrate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lesogaberan-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

levodropropizine CR-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MDR-16523-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ORB-110-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

orvepitant maleate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pemirolast potassium-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PHCA-01-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

S-1226-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

serlopitant-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ST-015-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ST-016-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ST-018-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XEND-0501-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cough-Dormant Projects

Cough-Discontinued Products

Cough-Product Development Milestones

Featured News & Press Releases

May 22, 2017: Merck Announces Presentation of Phase 2 Results for MK-7264, an Investigational, P2X3 Receptor Antagonist, Being Evaluated for the Treatment of Chronic Cough

Apr 27, 2017: BELLUS Health to present at Bloom Burton & Co. Healthcare Investor Conference

Apr 24, 2017: BELLUS Health Announces Grant of New U.S. Patent Covering Lead Compound for Chronic Cough

Sep 07, 2016: Patara Pharma Announces Positive Phase 2 Results for the Treatment of Refractory Chronic Cough in Patients with Idiopathic Pulmonary Fibrosis

May 16, 2016: Afferent Pharmaceuticals Presents Updated Positive Results with AF-219 from Phase 2B Chronic Cough Study at the 2016 American Thoracic Society International Conference

May 03, 2016: Patara Pharma Appoints Biotechnology Industry Leader John Schmid to Board of Directors

Apr 25, 2016: Afferent Pharmaceuticals Announces Presentation of Chronic Cough Clinical Data at the Upcoming American Thoracic Society 2016 International Conference

Sep 28, 2015: Afferent Pharmaceuticals Announces Positive Results in Phase 2b Chronic Cough Trial

Jul 01, 2015: Spriaso Announces Approval of New Drug Application for the Long Acting Codeine Antitussive With a Popular Anti-Histamine

Nov 25, 2014: Afferent Clinical Data Demonstrating AF-219 Treatment Reduces Cough Frequency by 75% in Chronic Cough Is Published In The Lancet

Sep 09, 2014: Charleston Laboratories Announces Key Clinical Updates for Novel Drug

Dec 11, 2013: Ario Pharma to Develop Novel Therapeutics for Respiratory Indications

Oct 10, 2013: Spriaso completes FDA Meeting on Tuxarin ER

Sep 09, 2013: Afferent Pharmaceuticals Reports Positive Phase 2 Clinical Data for the Company's Lead P2X3 Antagonist, AF-219

Jan 06, 2012: Tris Pharma Announces US Patent Grant Covering Platform Technology

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

Number of Products under Development for Cough, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

List of Tables

Number of Products under Development for Cough, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Cough-Pipeline by Alitair Pharmaceuticals Inc, H2 2017

Cough-Pipeline by AstraZeneca Plc, H2 2017

Cough-Pipeline by BELLUS Health Inc, H2 2017

Cough-Pipeline by Charleston Laboratories Inc, H2 2017

Cough-Pipeline by Conrig Pharma ApS, H2 2017

Cough-Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2017

Cough-Pipeline by Develco Pharma Schweiz AG, H2 2017

Cough-Pipeline by Grunenthal GmbH, H2 2017

Cough-Pipeline by Hyundai Pharmaceutical Co Ltd, H2 2017

Cough-Pipeline by Merck & Co Inc, H2 2017

Cough-Pipeline by Orbis Biosciences Inc, H2 2017

Cough-Pipeline by Patara Pharma Inc, H2 2017

Cough-Pipeline by PhytoHealth Corp, H2 2017

Cough-Pipeline by Pila Pharma AB, H2 2017

Cough-Pipeline by SolAeroMed Inc, H2 2017

Cough-Pipeline by Vernalis Plc, H2 2017

Cough-Dormant Projects, H2 2017

Cough-Dormant Projects, H2 2017 (Contd..1), H2 2017

Cough-Discontinued Products, H2 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Alitair Pharmaceuticals Inc

AstraZeneca Plc

BELLUS Health Inc

Charleston Laboratories Inc

Conrig Pharma ApS

Daewoong Pharmaceutical Co Ltd

Develco Pharma Schweiz AG

Grunenthal GmbH

Hyundai Pharmaceutical Co Ltd

Merck & Co Inc

Orbis Biosciences Inc

Patara Pharma Inc

PhytoHealth Corp

Pila Pharma AB

SolAeroMed Inc

Vernalis Plc

Cough Therapeutic Products under Development, Key Players in Cough Therapeutics, Cough Pipeline Overview, Cough Pipeline, Cough Pipeline Assessment


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand

person